Thermo Fisher Scientific's $13.6 Billion Acquisition of Life Technologies Boosts Flagging M&A Numbers May 01, 2013 | Press Release
Burrill Securities Launches Institutional Breakthrough Series April 29, 2013 | Press Release
Big Biotech Outpaces Big Pharma, Burrill & Company says April 16, 2013 | Press ReleaseSee all News
Sven RohmannManaging Director, General Manager Europe/Managing Director, Digital Health
Dr. Rohmann joined Burrill & Company in 2010 with a background in clinical medicine and basic research. He spent 10 years at Merck Serono, which provided him with a strong foothold in the pharmaceutical industry. His career exposed him to pre-clinical and clinical development, as well as marketing, business, and corporate development. During his tenure at Merck, he was involved in the successful licensing of Erbitux from ImClone and the establishment of Merck Oncology.
Prior to joining Burrill & Company, Dr. Rohmann worked as Venture Capital Fund Manager for Novartis Pharma AG, and as Managing Partner at Nextech Venture, both Switzerland. In addition, Dr. Rohmann served as CEO of two European biotech start-ups and gained board experience at three SME’s in Germany.
Dr. Rohmann’s brings a unique blend of scientific, pharma/biotech and venture knowledge, extensive network of contacts among healthcare providers, as well as academic and government research administrators, a thorough knowledge of European research and regulatory policies, and a significant experience in global, as well as European, partnering.
Dr. Rohmann received his MD from the University of Mainz, Germany, and his PhD from the Erasmus University, Rotterdam, Netherlands.